What Everads Therapy does

Everads Therapy is an Israeli medical device and drug delivery company founded in 2017 within the RAD Biomed Accelerator in Tel Aviv, developing a proprietary suprachoroidal space (SCS) delivery platform for retinal disease therapeutics. The core technology is a geometrically-optimized, non-sharp tissue separator that enables tangential injection into the suprachoroidal space, providing rapid and extensive distribution of therapies to the posterior segment and macula. The device is compatible with standard Luer lock syringes and is engineered to deliver high volumes and large particles, making it suitable for gene therapies, cell therapies, suspensions, and slow-release formulations. The underlying technology was licensed from Sheba Medical Center at Tel Hashomer, and the platform has been validated in more than 60 non-human primates across multiple modalities including AAV vectors, anti-VEGF antibodies, and nanoparticles. A first-in-human clinical trial in diabetic macular edema using triamcinolone acetonide suspension has been completed, with results published in Ophthalmology Science in 2026.

Name

Everads Therapy

Legal name

Everads Therapy

Website

https://everads-therapy.com

Company type

Private

Founded year

2017

Operating status

Operating

Headcount range

1–10 employees

Short description

Everads Therapy is an Israeli medical device company developing a proprietary suprachoroidal drug delivery platform for retinal disease therapies, licensing its injector technology to pharmaceutical and biotech partners including Kriya Therapeutics and VivaVision for gene therapy and small-molecule ocular applications.

Ownership category

akta.pro rank

Product category

Ophthalmic Drug Delivery Devices

NAICS

Surgical Appliance and Supplies Manufacturing (339113), Research and Development in Biotechnology (except Nanobiotechnology) (541714)

SIC

Surgical & Medical Instruments & Apparatus (3841), Patent Owners & Lessors (6794)

akta.pro primary industry

Ocular Drug Delivery Devices (Eye Droppers/Inserts) (HLAHAIAL)

akta.pro secondary industries

Gene Therapy Delivery Devices & Administration Systems (catheters, intrathecal, ocular delivery) (HLAAACAL), Cell Therapy Enabling Technologies (gene editing, cell engineering, delivery methods) (HLAAABAL)

Keywords

• Suprachoroidal drug delivery
• Retinal disease therapy
• Ophthalmic injection devices
• Ocular drug delivery
• Posterior segment delivery

Headquarters

HQ city

Tel Aviv

HQ country

Israel

HQ region

Middle East

Offices1 record

Markets served

GTM type

B2B

Offering type

Hardware or Manufacturing

Cost components

Technology or R&D, Personnel, Operations, Marketing or Sales, Supply Chain

Revenue model

1. Technology licensing: Everads licenses its suprachoroidal delivery technology to pharmaceutical and biotech companies for specific retinal targets. Partners pay pre-agreed license fees, development milestones, and royalties in exchange for exclusive or non-exclusive rights to use the technology for defined ocular targets.
2. Collaborative development partnerships: Co-development arrangements with partners where Everads provides its delivery technology while partners contribute development funding, with potential milestone payments and future royalty streams upon successful commercialization.

Go-to-market motion2 records

Distribution channels1 record

Marketing channels4 records

Core offering

Everads Therapy develops and licenses a proprietary suprachoroidal (SCS) drug and cell delivery platform — the Everads Suprachoroidal Injector — that uses a geometrically-optimized non-sharp tissue separator to enable tangential injection into the suprachoroidal space for targeted delivery of gene therapies, cell therapies, anti-VEGF antibodies, suspensions, and slow-release formulations to the posterior segment and macula for retinal disease treatment.

Product overview

Everads Therapy is an emerging startup developing a novel suprachoroidal delivery platform technology for retinal diseases. The core product is the Everads Suprachoroidal Injector (also referred to as the Everads Drug Delivery System), which enables targeted injection of therapies into the suprachoroidal space (SCS). The platform has been validated in over 60 non-human primates using various modalities including AAV vectors, anti-VEGF antibodies, nanoparticles, and other materials. The company is developing an early-stage pipeline leveraging this technology and has entered licensing and collaboration agreements with pharmaceutical partners including Kriya Therapeutics and VivaVision. The technology was founded in 2017 within the RAD Biomed Accelerator in Tel Aviv, with underlying technologies licensed from Sheba Medical Center.

Differentiator

Problem solved

Functional benefit

Products and services

• Everads Suprachoroidal Injector A novel suprachoroidal delivery device that enables targeted, rapid injection of therapies into the suprachoroidal space (SCS) for treatment of retinal diseases. The device features a proprietary geometrically-optimized non-sharp tissue separator that opens a path into the SCS, enabling tangential injection for rapid and extensive drug distribution to the posterior segment and macula. It is licensed to pharmaceutical and biotech partners.
• Everads Drug Delivery System A suprachoroidal space (SCS) delivery platform technology that facilitates targeted, rapid delivery of therapies to the choroid and retina. The system enables delivery of high volumes and large particles, supporting gene therapy, cell therapy, suspensions, and slow-release formulations for retinal disease treatment.

Quantifiable outcome

• Procedural feasibility demonstrated in office-based setting with thermal imaging confirming rapid, posteriorly directed drug distribution to posterior pole and macular region
• +1 more outcomes

Segments1 record

Ideal customer profiles1 record

Technology focussed Yes

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Feature4 records

Partnerships

Five partnerships are on record, tiered core and minor.

• Kriya TherapeuticscoreTechnology or Integration · 1 September 2023Exclusive license and collaboration agreement for development of ocular gene therapy candidates using Everads' suprachoroidal delivery technology. Kriya is developing gene therapies for prevalent ophthalmology diseases including geographic atrophy. Everads' technology enables improved distribution of gene therapies to the posterior segment and macula.
• VivaVisioncoreStrategic or Co-development Partner · 1 January 2023Collaboration to develop durable and effective therapies for retinal diseases. Delivery of VivaVision's best-in-class molecules via the suprachoroidal space using Everads' technology is expected to lead to novel treatments for retinal diseases.
• Israel Innovation AuthorityminorOthers · 1 July 2022Israel's Innovation Authority awarded a competitive grant to fund Everads' research and development. CEO Moshe Weinstein stated that the grant represents validation of the strong business and scientific case for Everads' technology and pipeline.
• Clinical-Stage Gene Therapy Company (unnamed)coreStrategic or Co-development Partner · 1 June 2021Collaboration to evaluate Everads' suprachoroidal delivery technology with a clinical-stage gene therapy company. Under the collaboration, the partner was given opt-in right to license specific retinal targets in exchange for pre-agreed license fees, development milestones and royalties.
• Global Pharmaceutical Company (unnamed)coreTechnology or Integration · 1 March 2020Option agreement with global pharma company to license Everads' suprachoroidal delivery system for retinal disease therapies. The agreement supports the potential of Everads' novel technology for delivery of posterior segment therapeutics to the suprachoroidal space. In August 2020, the company exercised rights for exclusive use of Everads' technology in specific retinal targets.

Scale indicators3 records

Recent moves6 records

Expansion highlights5 records

Emerging players

• Kriya Therapeutics: Kriya is an Everads partner developing gene therapies for prevalent ophthalmology diseases including geographic atrophy. While not a direct delivery device competitor, Kriya operates in the same ocular gene therapy value chain and represents both a customer and a strategic reference point for SCS-enabled therapeutics.
• Adverum Biotechnologies: Adverum develops AAV-based gene therapies for retinal diseases including wet AMD and diabetic macular edema, utilizing intravitreal delivery. Both Everads and Adverum compete in the broader ocular gene therapy delivery ecosystem with overlapping indication focus.
• 4D Molecular Therapeutics: 4DMT develops customized AAV vectors for retinal and other diseases with an active ocular gene therapy pipeline. Both companies serve the emerging gene therapy delivery market, with overlapping customer base of pharma partners developing retinal disease therapeutics.
• Kodiak Sciences: Kodiak develops novel biologics and conjugates (ABC platform) for retinal vascular diseases including wet AMD and DME. Both companies pursue improved durability of treatment for retinal diseases through differentiated therapeutic and delivery approaches.

Broad incumbents

• Santen Pharmaceutical: Santen is a global ophthalmology-focused pharmaceutical company with products for retinal diseases, glaucoma, and dry eye. As a large incumbent in ophthalmic therapeutics, Santen represents a potential licensing partner and competitor in the broader retinal disease treatment landscape.
• Ocular Therapeutix: Ocular Therapeutix develops sustained-release ocular drug delivery platforms including DEXTENZA for post-surgical ocular inflammation and pain. Both companies develop drug delivery technologies for ocular indications, though Ocular Therapeutix focuses on anterior segment while Everads targets posterior segment.
• Bausch + Lomb: Bausch + Lomb is a major ophthalmic pharmaceutical and device company with products across retinal diseases (e.g., Visudyne, enVista). Its broad portfolio in retinal therapeutics makes it a potential strategic acquirer or licensing partner for suprachoroidal delivery technology.

Direct peers

• Clearside Biomedical: Clearside is the most direct competitor in suprachoroidal space delivery, with its commercially approved XIPERE SCS Microinjector for macular edema and active partnerships with large pharma. Both companies target the SCS delivery route for posterior segment therapeutics with injection-based devices.
• REGENXBIO: REGENXBIO develops AAV gene therapies for retinal diseases (RGX-314) using suprachoroidal delivery, partnering with AbbVie. Both companies are pursuing SCS delivery as the enabling route for ocular gene therapy, addressing overlapping indications such as wet AMD and diabetic retinopathy.
• EyePoint Pharmaceuticals: EyePoint develops sustained-release ocular drug delivery technologies including DURYSTA and bioerodible implants for retinal diseases. Both Everads and EyePoint are ocular drug delivery platform companies targeting improved efficacy and durability of retinal disease treatments.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat5 records

Key risks7 records

Key highlights7 records

Customer concentration

Revenue estimate

Valuation estimate

Number of profiles

Profiles1 record

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Everads Therapy